MMR Announces 13 Health Information Technology Patents --

LOS ANGELES, CA--(Marketwired - Jun 16, 2014) - MMRGlobal, Inc. ( OTCQB : MMRF ), through its wholly owned subsidiary MyMedicalRecords, Inc. (collectively, "MMR"), today announced that it will receive U.S. Patent No. 8,768,725 (the '725 Patent) from the United States Patent and Trademark Office. The '725 patent includes claims directed to the sharing of records with a second healthcare provider to better manage and facilitate second opinions. MMR will now have a total of 36 patents including 13 domestic health information technology (HIT) patents, seven foreign HIT patents, and 16 biotech patents. Based on licenses pertaining to its U.S. patent portfolio, MMR already has agreements worth more than $40,000,000 as set forth in the agreements. In addition, ongoing royalties from sales and licensing including recurring revenues from retail and laboratory services could easily double that amount. MMR also projects revenue growth from domestic and international retail pharmacies, grocery retail, employee benefit programs, Etailers, affiliate marketers and other eHealth providers including 4medica and a recently signed Patent Agreement with Cerner Corp. For example, MMR expects online Etailer distribution to reach more than 40 million households each month and 12,000 in-store U.S. pharmacies this year. MMR also licensed distribution in European-based pharmacy retailers with more than 1,000 stores.

MyMedicalRecords, Inc. is a practicing entity and a leading provider of secure and easy-to-use Personal Health Records (PHRs) through its MyMedicalRecords PHR, and MMRPro and MMRProPlus document management and imaging systems for healthcare professionals . After issuance of Patent No. 8,768,725, MMR's patent portfolio will include 13 U.S. patents, including U.S. Patent Nos. 8,121,855; 8,117,045; 8,117,646; 8,301,466; 8,321,240; 8,352,287; 8,352,288; 8,498,883; 8,626,532, 8,645,161; 8,725,537, and including a NOA for Serial No. 13/082,896. The patents collectively include over 275 issued claims and there are additional pending applications and continuation applications. The '725 patent is scheduled to issue on July 1, 2014. MMR also has similar HIT patents and pending applications in 11 other countries or regional authorities of commercial interest including Australia, Canada, Singapore, New Zealand, Mexico, Hong Kong, China, Japan, South Korea, Israel, and Europe. 

The Company has three separate patent portfolios currently comprising the 36 patents and additional pending applications and continuation applications. The first is directed at Electronic Medical Records with a primary focus on Personal Health Records ; another portfolio centers around the use of PHRs in connection with Clinical Trials, which MMR plans on licensing through existing relationships with Big Pharma and the biotech community. The third portfolio includes MMRGlobal's legacy biotech patents from the Company's FavId™ vaccine trials and clinical research related to cancer-fighting anti-CD20 monoclonal antibodies.

Last month the Company also announced a Notice of Allowance for MMR's first Clinical Trials patent which includes 18 claims directed to methods and systems that provide for self-reporting being used to create Electronic Health Records for purposes including clinical trials. At the same time, MMR announced the issuance of U.S. Patent No. 8,725,537, entitled "Method and System for Providing Online Records," which expands MMR's health IT patents with claims directed toward storing, managing and sharing legal records. This patent broadens MMR's intellectual property beyond PHRs and other forms of Electronic Medical Records into the legal field. The '537 patent is particularly relevant to the management of wills and powers of attorney and advanced directives which can be included as part of an individual's Personal Health Record account.

Although MMR's primary business is as a provider and licensor of health IT products and services, the Company also has a portfolio of biotech patents. These pertain to cancer-fighting anti-CD20 monoclonal antibodies under the title, "Antibodies and Methods For Making and Using Them," issued in the U.S., Mexico, Australia and South Korea, with additional patents pending in the U.S., Australia, Brazil, Canada, China, Hong Kong, India, Europe, Japan and Korea, and additional patents pertaining to its B-cell idiotype vaccine worldwide. 

About MMRGlobal MMRGlobal, Inc., through its wholly-owned operating subsidiary, MyMedicalRecords, Inc., provides secure and easy-to-use online Personal Health Records ("PHRs") and electronic safe deposit box storage solutions, serving consumers, healthcare professionals, employers, insurance companies, financial institutions, retail pharmacies, and professional organizations and affinity groups. The MyMedicalRecords PHR enables individuals and families to access their medical records and other important documents, such as birth certificates, passports, insurance policies and wills, anytime from anywhere using the Internet. MyMedicalRecords is built on proprietary, patented technologies to allow documents, images and voicemail messages to be transmitted and stored in the system using a variety of methods, including fax, phone, or file upload without relying on any specific electronic medical record platform to populate a user's account. MMR's professional offering, MMRPro , is designed to give physicians' offices an easy and cost-effective solution to digitizing paper-based medical records and sharing them with patients through an integrated patient portal. Through its merger with Favrille, Inc. in January 2009, MMR acquired intellectual property biotech assets that include anti-CD20 antibodies and data and samples from its FavId™/Specifid™ vaccine clinical trials for the treatment of B-Cell Non-Hodgkin's lymphoma. To learn more about MMRGlobal, Inc. visit www.mmrglobal.com . View demos and video tutorials of MMR's products and services at www.mmrtheater.com . Follow us at Facebook.com/MMRGlobal and Twitter.com/mmrglobal .

Forward-Looking Statements All statements in this press release that are not strictly historical in nature, including, without limitation, intellectual property licenses, intellectual property enforcement actions, infringement claims or litigation, and future performance, management's expectations, beliefs, intentions, estimates or projections, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause MMR's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Some can be identified by the use of words (and their derivations) such as "need," "possibility," "potential," "intend," "offer," "development," "if," "negotiate," "when," "begun," "believe," "achieve," "will," "estimate," "expect," "maintain," "plan," and "continue," or the negative of these words. Actual outcomes and results of operations and the timing of selected events may differ materially from the results predicted, and any reported results should not be considered as an indication of future performance. Such statements are necessarily based on assumptions and estimates and are subject to various risks and uncertainties, including those relating to the possible invalidity of the underlying assumptions and estimates and possible changes or developments in economic, business, industry, market, legal and regulatory circumstances and conditions and actions taken or omitted to be taken by third parties, including customers, suppliers, business partners, potential licensees, competitors and legislative, judicial and other governmental authorities and officials. Factors that could cause or contribute to such differences include, but are not limited to: unexpected outcomes with respect to intellectual property enforcement actions, claims of intellectual property infringement and general intellectual property litigation; our ability to maintain, develop, license, monetize and protect our patent portfolio for both MMR's health IT and biotechnology intellectual property assets in the U.S. and internationally; the timing of milestone payments in connection with licensing our intellectual property; our ability to establish and maintain strategic relationships; changes in our relationships with our licensees; the risk MMR's products are not adopted or viewed favorably by the healthcare community and consumer retail market; business prospects, results of operations or financial condition; risks related to the current uncertainty and instability in financial and lending markets, including global economic uncertainties; the timing and volume of sales and installations; the length of sales cycles and the installation process; the market's acceptance of new product and service introductions; competitive product offerings and promotions; changes in government laws and regulations including the 2009 HITECH Act and changes in Meaningful Use and the 2010 Affordable Care Act; future changes in tax legislation and initiatives in the healthcare industry; undetected errors in our products; the possibility of interruption at our data centers; risks related to third party vendors; risks related to obtaining and integrating third-party licensed technology; risks related to a security breach by third parties; risks associated with recruitment and retention of key personnel; other litigation matters; uncertainties associated with doing business internationally across borders and territories; and additional risks discussed in MMR's filings with the Securities and Exchange Commission. MMR is providing this information as of the date of this release and, except as required by applicable law, does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.